Communiqués Insmed Incorporated

Actions

INSM

US4576693075

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
111,12 ^USD	+2,33%		-5,69%	-36,15%

21/09	Insmed annonce que la FDA accorde un examen prioritaire au dossier de demande d'extension d'indication pour l'Arikayce dans le traitement de la maladie pulmonaire à MAC	MT
21/09	Insmed Incorporated obtient une procédure d’examen prioritaire de la FDA pour une demande supplémentaire d’autorisation de mise sur le marché concernant Arikayce (amikacine liposomale en suspension pour inhalation) dans le traitement des maladies pulmonaires dues au complexe Mycobacterium avium	CI

Communiqués

21/09	FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027	PR
16/09	Insmed Expands Community Impact During Fifth Annual Global Day of Good	PR
04/09	Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026	AQ
04/09	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
03/09	Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026	PR
26/08	Insmed to Present at September 2026 Investor Conferences	PR
24/08	BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease	PR
06/08	Insmed: Q2 Earnings Snapshot	AQ
06/08	Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update	PR
23/07	Insmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026	PR
16/07	Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension	PR
23/06	Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory	PR
05/06	Insmed Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	AQ
04/06	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
27/05	Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference	PR
07/05	Insmed: Q1 Earnings Snapshot	AQ
07/05	Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update	PR
06/05	Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis	PR
04/05	Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026	PR
30/04	Insmed to Present at May 2026 Investor Conferences	PR
23/04	Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026	PR
07/04	Insmed Provides Clinical Update on Phase 2b CEDAR Study	PR
23/03	Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease	PR
05/03	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	PR
19/02	Insmed: Q4 Earnings Snapshot	AQ